← Back to Screener
VolitionRX Limited Common Stock (VNRX)
Price$0.18
Favorite Metrics
Price vs S&P 500 (26W)-77.60%
Price vs S&P 500 (4W)-20.32%
Market Capitalization$27.16M
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)9.49x
Revenue Growth (3Y)77.29%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-35.74%
Net Profit Margin (TTM)-1352.16%
EPS (TTM)$-0.22
10-Day Avg Trading Volume4.22M
EPS Excl Extra (TTM)$-0.22
Revenue Growth (5Y)180.21%
EPS (Annual)$-0.22
ROI (Annual)-122.64%
Net Profit Margin (5Y Avg)-9529.48%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)133.24%
ROA (Last FY)-338.45%
Revenue Growth TTM (YoY)40.04%
EBITD / Share (TTM)$-0.18
ROE (5Y Avg)-136.80%
Operating Margin (TTM)-1258.48%
Cash Flow / Share (Annual)$-0.16
P/B Ratio4.65x
P/B Ratio (Quarterly)18.58x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)21.75x
Net Interest Coverage (TTM)-8.44x
ROA (TTM)-305.57%
EPS Incl Extra (Annual)$-0.22
Current Ratio (Annual)0.17x
Quick Ratio (Quarterly)0.13x
3-Month Avg Trading Volume8.42M
52-Week Price Return-65.95%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.07
P/S Ratio (Annual)15.73x
Asset Turnover (Annual)0.25x
52-Week High$0.94
Operating Margin (5Y Avg)-9964.11%
EPS Excl Extra (Annual)$-0.22
CapEx CAGR (5Y)-45.94%
Tangible BV CAGR (5Y)-2.94%
26-Week Price Return-73.61%
Quick Ratio (Annual)0.13x
13-Week Price Return-49.71%
Total Debt / Equity (Annual)0.22x
Current Ratio (Quarterly)0.17x
Enterprise Value$37.575
Revenue / Share Growth (5Y)140.82%
Asset Turnover (TTM)0.23x
Book Value / Share Growth (5Y)-16.26%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1360.63%
Cash / Share (Annual)$0.01
3-Month Return Std Dev89.83%
Net Income / Employee (TTM)$-0
ROE (Last FY)-149.44%
Net Interest Coverage (Annual)-8.44x
EPS Basic Excl Extra (Annual)$-0.22
Receivables Turnover (TTM)8.06x
Total Debt / Equity (Quarterly)0.79x
EPS Incl Extra (TTM)$-0.22
Receivables Turnover (Annual)8.06x
ROI (TTM)-191.86%
P/S Ratio (TTM)15.73x
Pretax Margin (5Y Avg)-9606.40%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.33
Price vs S&P 500 (52W)-95.78%
Year-to-Date Return-33.10%
5-Day Price Return-0.81%
EPS Normalized (Annual)$-0.22
ROA (5Y Avg)-202.93%
Net Profit Margin (Annual)-1352.17%
Month-to-Date Return-15.35%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-0.19
Operating Margin (Annual)-1258.47%
LT Debt / Equity (Annual)0.14x
ROI (5Y Avg)-107.56%
LT Debt / Equity (Quarterly)0.49x
EPS Basic Excl Extra (TTM)$-0.22
P/TBV (Quarterly)18.81x
P/B Ratio (Annual)9.37x
Pretax Margin (TTM)-1360.63%
Book Value / Share (Annual)$0.33
Price vs S&P 500 (13W)-50.39%
Beta1.29x
P/FCF (Annual)679.09x
Revenue / Share (TTM)$0.01
ROE (TTM)-376.59%
52-Week Low$0.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.92
3.92
4.00
4.00
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VNRXVolitionRX Limited Common Stock | 15.73x | 40.04% | — | — | $0.18 |
IDXXIdexx Laboratories Inc | 10.59x | 10.42% | 61.80% | 14.28% | $569.95 |
LNTHLantheus Holdings, Inc | 3.53x | 0.50% | 61.10% | 40.71% | $83.92 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 299.06x | -5.72% | 89.00% | — | $27.80 |
CLDXCelldex Therapeutics, Inc | 1718.98x | -77.98% | 17.65% | — | $33.86 |
NEOGNeogen Corp | 2.32x | -3.91% | 45.20% | — | $9.24 |
NTLAIntellia Therapeutics, Inc | 26.08x | 16.92% | — | — | $14.16 |
QDELQuidelOrtho Corporation Common Stock | 0.31x | -1.89% | 46.67% | — | $12.69 |
MYGNMyriad Genetics Inc | 0.58x | -1.56% | 69.93% | — | $5.00 |
ACHVAchieve Life Sciences, Inc. | 14.37x | -89.25% | — | — | $4.81 |
TKNOAlpha Teknova, Inc. Common Stock | 3.62x | 7.35% | 33.17% | — | $2.68 |
About
VolitionRX Ltd develops blood-based diagnostic tests using its proprietary Nucleosomics platform to identify disease markers from circulating nucleosomes. The company's tests provide simple, cost-effective alternatives for diagnosing and monitoring cancers, sepsis, COVID-19, and other serious diseases. VolitionRX operates in both human and veterinary diagnostics, targeting underserved markets with accessible diagnostic solutions.